Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression
Ryan Stuchbery, Geoff Macintyre, Marek Cmero, Laurence M Harewood, Justin S Peters, Anthony J Costello, Christopher M Hovens, Niall M Corcoran
ONCOTARGET | IMPACT JOURNALS LLC | Published : 2016
BACKGROUND: Despite the importance of androgen receptor (AR) signalling to prostate cancer development, little is known about how this signalling pathway changes with increasing grade and stage of the disease. OBJECTIVE: To explore changes in the normal AR transcriptome in localised prostate cancer, and its relation to adverse pathological features and disease recurrence. DESIGN: Publically accessible human prostate cancer expression arrays as well as RNA sequencing data from the prostate TCGA. Tumour associated PSA and PSAD were calculated for a large cohort of men (n=1108) undergoing prostatectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed a meta-analysis of the expressio..View full abstract
Related Projects (1)
Investigation of the source of new testosterone production in prostate tumours that become resistant to existing hormonal (testosterone lowering and blocking) therapies
Prostate cancer is critically dependent upon continued testosterone stimulation, even when the disease becomes resistant to existing hormona..
Awarded by NHMRC
This work is supported by a project grant from the NHMRC, ID: 1024081. The Australian Prostate Cancer Centre Epworth is supported by the Australian Government as represented by the Department of Health and Ageing. N.M.C. is supported by a David Bickart Clinician Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.